Alcidion Expands Partnership with NextGate to UK Market

Alcidion LtdSmart health tech provider Alcidion Group Limited (ASX:ALC) has announced an expansion of its reseller agreement with NextGate to include the UK and Ireland.

In 2018, MKM Health (which was acquired by Alcidion in 2018) signed an agreement to resell NextGate's market leading Enterprise Master Patient Index (EMPI) and Provider Registry solutions in Australia and New Zealand. Following a successful two-year relationship, this agreement has now been extended to also include the UK and Ireland.

NextGate is the global leader in healthcare enterprise identification, helping healthcare organisations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data.

Alcidion's reseller agreement with NextGate has resulted in two significant state-wide contracts in Australia. The Queensland Health Referral Service Directory based on the Provider Index was delivered by Alcidion working closely with NextGate. For the Victorian Department of Health and Human Services Unique Patient Identification program, Alcidion supported NextGate in delivery of its EMPI capability.

The expansion of the agreement to the UK and Ireland will further strengthen Alcidion's ability to support NHS trusts, health boards and region wide integrated care systems. The news follows the Alcidion's formal launch this summer of its Miya Precision product as the first smart clinical asset for the NHS.

Lynette Ousby, UK General Manager of Alcidion, said: "With the current focus in the NHS on consolidating clinical systems across regions, the ability to include the offering of NextGate solutions to complement our Miya Precision capability, establishes a true enterprise approach to healthcare delivery."

Alcidion's Miya Precision presents the NHS with an opportunity to move beyond static electronic records to technology that engages healthcare professionals. Early adopters are using the platform to orchestrate information across disparate systems using modern technology from Alcidion based on the FHIR standard and to establish smart clinical engagement supported by tailored clinical decision support.

With the ability to allow NHS organisations to use data to automate routine tasks, care plans and pathways, Miya Precision is being seen as a way to realise more value from electronic patient record investments and to provide a technology orchestration layer in trusts and for entire regions.

The addition of the NextGate Patient and Provider Registries, which are built on the MatchMetrix® master identity platform, will extend that capability to effectively manage identity for both patients and healthcare providers.

"We are delighted to expand our partnership with Alcidion to facilitate a modernised NHS infrastructure where patients are accurately identified and consistently matched to their health and social care data," said Andy Aroditis, CEO of NextGate. "Together, Alcidion and NextGate are delivering innovative interoperable solutions that maximise the quality, efficiency and coordination of care."

Alcidion Managing Director, Kate Quirke commented: "I am delighted that we can now expand our success implementing the NextGate solution in Australia to the UK. The combination of our service delivery and domain expertise with the powerful capabilities of MatchMetrix creates a compelling opportunity for the health sector to establish first class identity management."

About NextGate

With over 200 customers in six countries, NextGate is the global leader in healthcare enterprise identification. Committed to helping organizations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data, our full suite of identity matching solutions connects the entire healthcare ecosystem to drive critical improvements in quality, efficiency and safety. NextGate’s market leading EMPI currently manages 300 million lives and is deployed by the nation’s most successful healthcare systems and health information exchanges.

About Alcidion

Alcidion (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patientrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

Most Popular Now

Accelerating Data Solutions to Save LIVE…

The consortium of COVID-X announces the launch of the ​1st Open Call ​framed in a ​2-year initiative that will invest ​4 million € to fast-track to market 30+ European data...

Significant Disparities in Telemedicine …

After "COVID-19," the term that most people will remember best from 2020 is likely to be "social distancing." While it most commonly applied to social gatherings with family and friends...

Model Used to Evaluate Lockdowns was Fla…

In a recent study, researchers from Imperial College London developed a model to assess the effect of different measures used to curb the spread of the coronavirus. However, the model...

New Virtual Screening Strategy Identifie…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang...

Using Artificial Intelligence to Find Ne…

Scientists have developed a machine-learning method that crunches massive amounts of data to help determine which existing medications could improve outcomes in diseases for which they are not prescribed. The intent...

FDA Releases Artificial Intelligence / M…

Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach...

One in Four Doctors Attacked, Harassed o…

While many physicians benefit from social media by networking with potential collaborators or interfacing with patients, a new study from Northwestern University and the University of Chicago found many physicians...

CliniSys Launches Laboratory Information…

CliniSys has launched a new laboratory information management system for genomic laboratories in the UK. The company has brought GLIMS Genomics to the UK from Europe, where it is being...

The Institute of Healthcare Management C…

The Institute of Healthcare Management has called for honest and open communication about NHS capacity after a snapshot survey revealed the scale of sickness absence across the service. The UK's leading...

First NHS Trust and Sectra Achieve Rapid…

A new region-wide approach to analysing x-rays, MRI scans, CT scans, mammography, and an entire range of crucial diagnostic images, has started to become reality, now that The Pennine Acute...

Bayer Transforms Pharma Business through…

At its virtual Pharma Media Day, Bayer presented exciting progress in transforming its pharmaceutical business with breakthrough innovation in healthcare that will significantly help patients suffering from conditions that are...